ALFA Finder| Management target | Revenue 25.0% FY27 |
|---|
| Revenue growth | 13.7% YoY growth in Q1 FY27. |
|---|---|
| Margins | EBITDA margin at 36.4%; moderated QoQ due to facility expenses and labor. |
| Order book | Healthy enquiries and orders in clinical research; first Biologics client onboarded. |
| Demand visibility | Positive enquiry trends in Pharma and Electronics; Biologics first order secured. |
| Management confidence | High; optimistic on maintaining growth momentum despite near-term regional headwinds. |
Growth
Revenue grew 13.7% YoY; EBITDA increased 16% to INR 411 million; PAT rose 11.4% to INR 210 million.
Outlook
FY27 capex budget of INR 80 crores. Management aims to maintain or exceed 20-25% growth momentum annually.
Risks
Global geopolitical challenges in the Middle East impacting food import/export volumes; currency appreciation and new labor laws.
Last quarter's promises, checked
Delivered
- Guided 35% EBITDA margin → delivered 36.4% (= BEAT)
- Guided entry into Biologics FY27 → delivered first order secured (= BEAT)
- Guided net debt-free status → delivered net debt-free (= BEAT)
Partly delivered
- Guided INR 500cr revenue run rate by Q4 FY26 → delivered INR 416.3cr FY26 (= PARTIAL)
Missed
- Guided 20-25% CAGR growth → delivered 13.7% YoY (= MISS)
Investor Presentation filed with NSE, NSE: VIMTALABS. Summary written with AI assistance from the document.
Vimta Labs Ltd: key numbers
- Share price
- ₹507.95
- Market cap
- ₹2,271 Cr
- Revenue (annual)
- ₹407.3 Cr
- Net profit (annual)
- ₹77.51 Cr
- P/E (TTM)
- 28.3×Sector 54.5×
- Promoter holding
- 35.64%-0.03% QoQ
- FII holding
- 5.07%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vimta Labs Ltd
All →Vimta Labs Merger & Restructuring Worth ₹0.08 Cr
Vimta Labs incorporated wholly owned US subsidiary Vimta Labs LLC, investing about INR 0.08 Crore (USD 8,500). The contract research unit supports the parent's testing business.
- Value
- ₹0.08 Cr
Vimta Labs Earnings Call Transcript: Key Takeaways
Stable Q2 performance masked by R&D lulls and logistics headwinds.
- Call
- Guides 25% growth
Vimta Labs Results Update
Vimta Labs reported Q2 FY27 income of ₹1,149 Mn, up 9.9% YoY, and PAT of ₹206 Mn at 17.9% margin. EBITDA margins held steady at 35.5%.
Vimta Labs Investor Presentation: Key Takeaways
Q2 FY27: total income Rs1,149Mn (+9.9% YoY), EBITDA Rs408Mn (35.5% margin), PAT Rs206Mn (17.9% margin, +3.5% YoY). H1 FY27 PAT Rs417Mn (+7.3%).
Vimta Labs Q2 FY27 Results: Net Profit ₹20.6 Cr, Up 3.5% YoY
Vimta Labs Ltd reported revenue from operations of ₹112 Cr (+10.0% YoY) and net profit of ₹20.6 Cr (+3.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹20.6 Cr · +3.5% YoY
Vimta Labs Board Meeting Date
Vimta Labs will hold a board meeting on 30 October 2026 to consider half-year results. Trading window stays closed from 01 October.